Decheng Capital »

Cg Oncology shares owned by Decheng Capital

Quarter-by-quarter ownership of Cg Oncology shares owned by Decheng Capital from 13F filings

Historical chart of Decheng Capital investment in Cg Oncology

Tip: Access up to 7 years of quarterly data

All positions including Cg Oncology held by Decheng Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cg Oncology by Decheng Capital

Quarter filed Position value Share count Share price at filing
2024-03-31 $240M 5.5M 43.90

More positions owned by Decheng Capital

Alpine Immune Sciences (ALPN)
Cg Oncology
Zentalis Pharmaceuticals (ZNTL)
Illumina (ILMN)
BeyondSpring SHS (BYSI)
Arcus Biosciences Incorporated (RCUS)
Krystal Biotech (KRYS)
4d Molecular Therapeutics In (FDMT)
Equillium (EQ)
Phathom Pharmaceuticals (PHAT)
Helix Acquisition Corp
Crinetics Pharmaceuticals In (CRNX)
10x Genomics Cl A Com (TXG)
Cytokinetics (CYTK)
Legend Biotech Corp- Adr (LEGN)

View all positions for Decheng Capital

Top funds holding Cg Oncology

Decheng Capital
TCG Crossover Management
BlackRock
Vanguard Group
BVF
Henderson Group
Avidity Partners Management
RA Capital Management
Perceptive Advisors
Braidwell
T. Rowe Price Associates
Alliancebernstein
ABG-WTT Global Life Science Capital Partners GP
Franklin Resources
Cormorant Asset Management

View all funds holding Cg Oncology